-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
An estimated 15 million premature babies are born each year, making it the leading cause of infant death worldwide.
few indicators predict which pregnancies lead to premature birth, but inflammation of the reproductive tract is one of the causes of about one-third of cases.
not only puts babies at risk of being born underweight and stunted lungs, but is also linked to brain damage in developing fetuses.
the new report using technology developed by scientists at the Johns Hopkins University School of Medicine's Nanomedical Center.
its active ingredients are two drugs: progesterone, a hormone that regulates female reproduction, and trichostatin A,TSA, a histone deacetylase (HDAC) inhibitor that regulates gene expression.
to prepare the nanosurfed agent, the drug was first ground into tiny crystals (i.e. nanocrystals) about 200-300 nanometers in diameter.
these nanocrystals are then coated with a stable compound to prevent them from falling into protective mucus layers in the body that absorb and remove foreign particles.
, an associate professor of ophthalmology at Johns Hopkins University School of Medicine, said, "This means that we can use fewer drugs that can effectively reach other parts of the female reproductive tract."
to test the nanoshanger, the researchers used genetically modified mice to simulate inflammatory-related symptoms that lead to premature birth in humans.
they found that the experimental nanosurfed agent could prevent premature birth in these mice.
tested the nervous system of young mice born to treated female mice and found no abnormalities.
the researchers also applied a combination of the drug to human uterine cells grown in the lab.
they reported that the drug composition reduced the contraction of the samples in the subjects.
they need to conduct more laboratory tests on the experimental nanosurger to assess its safety before considering clinical trials in humans.
: 1.Hannah C. Zierden et al. Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth. Science Translational Medicine, 2021, doi:10.1126/scitranslmed.abc6245. 2.Nanotechnology prevents premature birth in mouse studies
